A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Trial Profile

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs ALT 803 (Primary) ; BCG
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 May 2017 Results of phase I portion of this study (n=9) presented at the 112th Annual Meeting of the American Urological Association
    • 02 May 2017 According to an Altor BioScience Corporation media release, results from the recently completed Phase Ib portion of this trial will be presented at the American Urological Association Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top